Malignant transformation of cells depends on accumulation of DNA damage. Over the past
years we have learned that the T cell–based immune system frequently responds to the …

The remarkable success of immune checkpoint inhibitors demonstrates the potential of
tumour-specific CD8+ T cells to prevent and treat cancer. Although the number of lives …

Although mutations in DNA are the best-studied source of neoantigens that determine
response to immune checkpoint blockade, alterations in RNA splicing within cancer cells …

Cytotoxic T cells are of central importance in the immune system's response to disease.
They recognize defective cells by binding to peptides presented on the cell surface by MHC …

Throughout the body, T cells monitor MHC-bound ligands expressed on the surface of
essentially all cell types. MHC ligands that trigger a T cell immune response are referred to …

The set of peptides presented on a cell's surface by MHC molecules is known as the
immunopeptidome. Current mass spectrometry technologies allow for identification of large …

Presentation of tumor-specific or tumor-associated peptides by HLA class I molecules to
CD8+ T cells is the foundation of epitope-centric cancer immunotherapies. While often in …

The clinical benefits of immune checkpoint blockage (ICB) therapy have been widely
reported. In patients with cancer, researchers have demonstrated the clinical potential of …

Defining the repertoire of peptides presented by the major histocompatibility complex class I
(MHC I) is a key step toward the identification of relevant antigens for cancer …

Immunopeptidomics employs the use of mass spectrometry to identify and quantify peptides
presented on the surface of cells by major histocompatibility complex (MHC; human …